Literature DB >> 16289766

Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.

Kai Schulze1, Eva Medina, Carlos A Guzmán.   

Abstract

Streptococcus pyogenes is a human pathogen causing invasive and non-invasive diseases, as well as severe sequels, such as rheumatic fever. Several bacterial factors have been proposed as candidate vaccine antigens. Among them, the serum opacity factor (SOF), which was able to confer protective immunity against an intraperitoneal challenge after vaccination by the parenteral route. In an attempt to develop more efficient vaccines, we combined SOF with an additional well-known protective antigen, namely, the fibronectin-binding protein I (SfbI). Intranasal immunization of mice with SOF and SfbI stimulates strong systemic and mucosal immune responses against both antigens. Animals vaccinated with SfbI, alone or in combination with SOF, were also efficiently protected against a lethal challenge with a SOF/SfbI-positive virulent S. pyogenes strain (80% survival). In contrast, those vaccinated with SOF alone were not protected against a mucosal challenge (100% lethality), which mimics more closely natural infections. These results highlight the importance of developing adequate experimental animal models to evaluate vaccine efficiency, according to the selected antigen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289766     DOI: 10.1016/j.vaccine.2005.06.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets high-density lipoproteins.

Authors:  Harry S Courtney; Henry J Pownall
Journal:  J Biomed Biotechnol       Date:  2010-07-08

3.  Identification and experimental verification of protective antigens against Streptococcus suis serotype 2 based on genome sequence analysis.

Authors:  Lina Liu; Gong Cheng; Changjun Wang; Xiuzhen Pan; Yanguang Cong; Qu Pan; Jing Wang; Feng Zheng; Fuquan Hu; Jiaqi Tang
Journal:  Curr Microbiol       Date:  2008-10-07       Impact factor: 2.188

4.  Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.

Authors:  Tania Rivera-Hernandez; Manisha Pandey; Anna Henningham; Jason Cole; Biswa Choudhury; Amanda J Cork; Christine M Gillen; Khairunnisa Abdul Ghaffar; Nicholas P West; Guido Silvestri; Michael F Good; Peter M Moyle; Istvan Toth; Victor Nizet; Michael R Batzloff; Mark J Walker
Journal:  mBio       Date:  2016-06-14       Impact factor: 7.867

5.  Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.

Authors:  Rasmus Mortensen; Dennis Christensen; Lasse Bøllehuus Hansen; Jan Pravsgaard Christensen; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

6.  Immunogenicity and Safety of a Chemically Synthesized Divalent Group A Streptococcal Vaccine.

Authors:  Yongxiang Wu; Suhua Li; Yanting Luo; Yunyue Zhao; Jiarui Wang; Ruimin Dong; Xujing Xie; Jieming Zhu; Jinlai Liu
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-02-28       Impact factor: 2.471

7.  A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.

Authors:  Shuai Bi; Meiyi Xu; Ya Zhou; Xinxin Xing; Adong Shen; Beinan Wang
Journal:  mBio       Date:  2019-11-26       Impact factor: 7.867

Review 8.  Towards developing a vaccine for rheumatic heart disease.

Authors:  Geethanjali Devadoss Gandhi; Navaneethakrishnan Krishnamoorthy; Ussama M Abdel Motal; Magdi Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2017-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.